While maintaining our wait-for-a-pullback 2 rating for the time being, we’re increasing our price target to $250 per share from $240.
Schlagwort-Archiv: CNBC
Amazon crushed it in e-commerce and cloud, forecast an impressive holiday quarter
We’re reiterating our 1 rating and raising our price target to $240 price target from $220.
Linde falls after its guidance fails to wow the market. We’ve seen this movie before
Shares of the industrial gas supplier dropped around 3% in a down market.
Thursday’s big stock stories: What’s likely to move the market in the next trading session
The Nasdaq Composite touched a new high during Wednesday’s trading, but ultimately ended the day lower. Here’s what CNBC is watching going into Thursday.
Jack Dorsey’s payments company Block expands corporate card service to the UK
Block, the payments company owned by tech billionaire Jack Dorsey, has launched its corporate card service in the U.K.
Chinese smartphone company Honor gets new investors as it gears up for IPO
Chinese smartphone company Honor on Thursday announced backing from new investors as the Huawei spinoff prepares for an initial public offering.
Sigh of relief for UK tech founders as Labour hikes capital gains tax by less than feared
Britain’s Labour government on Wednesday announced plans to raise the rate of capital gains tax on sales of shares — the move was less severe than feared.
Peloton raises its full-year profit guidance, but expects the holiday quarter to be softer than expected
Peloton’s cash flows are improving, but it’s expecting to sell fewer bikes and treadmills during its holiday quarter than Wall Street expected.
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
The pharmaceutical giant also raised its full-year revenue forecast to an increase of roughly 5%.
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.